What Are the Signs of PML in Tysabri Patients?

Latest update (2026-07)

From General Health to Specific Risk: The Legacy of Safety Information

If you or a loved one is taking Tysabri, knowing the early signs of progressive multifocal leukoencephalopathy (PML) can be critical. The medical community's evolving understanding of drug safety—built on decades of pharmacovigilance—provides a framework for recognizing these symptoms. This page outlines the key warning signs and FDA-recommended monitoring protocols.

Tysabri and PML: A Documented Causal Link

Tysabri (natalizumab) is a monoclonal antibody used primarily in the treatment of multiple sclerosis and Crohn's disease. Its association with progressive multifocal leukoencephalopathy (PML) is a well-documented and serious safety concern, as reflected in the FDA's boxed warning. PML is an opportunistic viral infection of the brain caused by the JC virus, which typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA has identified three key risk factors that increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical trial data provide evidence of the causal link between Tysabri and PML. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these patients had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the importance of monitoring for PML symptoms throughout treatment.

Mechanism and Risk Factors: How Tysabri Increases PML Risk

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JC virus to reactivate and cause PML. The risk is particularly elevated in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This suggests that risk increases with longer exposure, though cases can occur earlier. The FDA advises that healthcare professionals should monitor patients on Tysabri for any new sign or symptom suggestive of PML, and dosing should be withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

FDA Warnings and the TOUCH Prescribing Program

The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and the TOUCH Prescribing Program. The boxed warning clearly states that Tysabri increases the risk of PML and outlines risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program aims to ensure that patients are informed of the risks and that monitoring is conducted appropriately. For affected patients, causation-related considerations are critical. The presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use are established risk factors that can help assess individual risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may experience symptoms such as fatigue, headache, gait disturbance, memory impairment, and cognitive disorder, which are also among the most frequently reported adverse events in FAERS data for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). However, these symptoms are nonspecific, and PML diagnosis requires clinical evaluation and imaging.

Conclusion: Evidence and Vigilance

In summary, the evidence establishes a clear causal link between Tysabri and PML, with risk factors including anti-JCV antibodies, treatment duration, and prior immunosuppressant use. The FDA has implemented warnings and a restricted distribution program to mitigate risk, but patients and healthcare providers must remain vigilant for symptoms of PML throughout treatment. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the causal link between Tysabri and PML?

Tysabri (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. Clinical trials documented three cases of PML in Tysabri-treated patients, establishing a causal link. The FDA has issued a boxed warning and identified risk factors including anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the FDA warnings for Tysabri and PML?

The FDA requires a boxed warning stating that Tysabri increases the risk of PML. It is only available through the TOUCH Prescribing Program, a restricted distribution program that ensures patients are informed of risks and monitored appropriately. Healthcare professionals must withhold Tysabri at the first sign or symptom of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The three key risk factors are: presence of anti-JCV antibodies (indicating prior JC virus exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications. These factors should be considered when assessing individual risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. DailyMed - Tysabri Label
  2. FDA Adverse Event Reporting System - Tysabri

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Protect your rights. Start your claim process here.

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.